Drugs / TRL345
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05408091 | Sep 2023 → Dec 2024 | — | Trellis Bioscience LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRL345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05408091 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody” NCT05408091 ↗ |
| Route | Intravenous | “via IV infusion” NCT05408091 ↗ |